Buy Cediranib(AZD2171)|288383-20-0|Inhibitors|from supplier chembestbuy.com|Research only

Home

Add Favorites

Search Product

Live Chat

E-mail

Pharmacology

Inhibitors

Receptors

Hedgehog Signaling Pathway

Research Area

Cardiovascular System

Product Type

Vitamin D series compounds

Toxins

　 More +

Browse Alphabetically by Name

ALL	A	B	C	D	E	F
G	H	I	J	K	L	M
N	O	P	Q	R	S	T
U	V	W	X	Y	Z	Others

CL1631 Cediranib(AZD2171) (288383-20-0)

Catalog No.:	CL1631
CAS No.:	288383-20-0
Synonym:	AZD2171
Chemical Name:	4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Molecular Formula:	C₂₅H₂₇FN₄O₃
Molecular Weight:	450.51

Technical Data:

Appearance:	Light yellow powder
Solubility:	Soluble in Methanol, acetic ester,Dichloromethane, hardly soluble in water
Purity:	>99%
Storage:	at +4℃
Original QC Data:
Shipping Conditions:	Ambient Temp.

Price and Availability of Cediranib(AZD2171):

Size	Price	Stock
50 mg	USD 266	In stock
100mg	USD 476	In stock

Biological Activity:

Cediranib (AZD2171) is a once-daily oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. Phase 1 studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less.

References:

1. Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400.
2. Morton CL, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer, 2012, 58(4), 566-571.

View Related Products by Target:

Vandetanib

Vorinostat(SAHA)

Tozasertib(VX-680)

Lenalidomide(CC-5013)

Sunitinib Malate(Sutent)